Tech Company Financing Transactions
Tau Therapeutics Funding Round
On 12/18/2012, Tau Therapeutics secured $3 million in funding from private investors.
Transaction Overview
Company Name
Announced On
12/18/2012
Transaction Type
Venture Equity
Amount
$3,000,000
Round
Undisclosed
Investors
Proceeds Purpose
The proceeds will support Tau's Phase 1b clinical trial currently being conducted with the National Cancer Institute's Adult Brain Tumor Consortium. Additionally, the proceeds will support development of new therapies and diagnostics in multiple indications.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
600 East Water St. E
Charlottesville, VA 22902
USA
Charlottesville, VA 22902
USA
Phone
Website
Email Address
Overview
Tau Therapeutics is a biotechnology company built on a revolutionary discovery of a Cytostatic Checkpoint Therapy TM that stops the growth of cancer cells. As the proprietors of this disruptive mechanism of action, Tau is focused on the research, development, repositioning and commercialization of calcium T-channel therapy agents.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Andrew Krouse
Chief Medical Officer
Bruce Silver
Founder
Lloyd Gray
Founder
Timothy Macdonald
VP - Bus. Development
John McCray
Browse more venture capital transactions:
Prev: 12/18/2012: Appfluent Technology venture capital transaction
Next: 12/18/2012: Tarveda Therapeutics venture capital transaction
Share this article
Where The Data Comes From
We do our best to report on tech company VC transactions. VC transactions on this site are sourced from company press releases and news coverage. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs